Technology ID
E-254-2013-2

Novel Rift Valley Fever Virus Vaccines

Linked ID
TAB-2696
Inventors
Brian Bird (CDC)
Cesar Albarino (CDC)
Stuart Nichol (CDC)
Thomas Ksiazek (CDC)
Lead Inventors
Brian Bird (CDC)
Co-Inventors
Cesar Albarino (CDC)
Stuart Nichol (CDC)
Thomas Ksiazek (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Rift Valley fever (RVF) virus vaccine development or improvement
  • Prevention of RVF virus infection in livestock and humans
  • Biodefense, biosecurity
This invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective immunity following a single injection, and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. Additionally, this technology relates to a method of using reverse genetics to generate recombinant RVF viruses.
Competitive Advantages
  • In vivo evidence shows single-dose protection
  • Allows for discrimination between vaccinated and naturally-infected subjects
  • Useful for controlled screening of therapeutic compounds

Request More Info

Licensing Contact